Dopamine May Be a Safer Antiangiogenic Drug for Malignant Tumors
the Cancer Therapy Advisor take:
Vascular endothelial growth factor-A has a well-established role in tumor angiogenesis. Today, a variety of different cancer types and clinically treated via molecules that target vascular endothelial growth factor-A or its receptors.
The downside to the use of these antiangiogenic agents is that they are expensive and can produce serious adverse events in the patients who are being treated. It is necessary for researchers to focus on finding new drugs that have manageable risks and side effects in order to better to treat patients.
Researchers continued from the experimental model findings that revealed dopamine inhibits vascular endothelial growth factor-A-induced angiogenesis to investigate whether dopamine treatment produces toxicities that are similar to other antiangiogenic agents.
The researchers found that dopamine administered at 50 mg/kg/d x 7 days ip inhibited tumor angiogenesis and growth of both human colon cancer and lung cancer in mice without causing the typical side effects such as hypertension, hematological toxicities, renal toxicities, or hepatic toxicities.
Dopamine also prevented the development of neutropenia that is generally induced by 5-fluorouracil in the mice with colon cancer. Further research is need to confirm that the treatment is safe and effective in humans with these cancer types, but the promising results may indicate promise for the use of dopamine as a safer and more effective antiangiogenic drug for patients with cancer.
Vascular endothelial growth factor-A has a well-established role in tumor angiogenesis.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- CTC Screening May Be Effective Method for Preventing Colorectal Cancer
- Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors
- Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC
- Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC
- Alcohol Consumption and Cancer